-
Lapatinib (INN), used in the form of
lapatinib ditosylate (USAN) (trade
names Tykerb and
Tyverb marketed by Novartis) is an
orally active drug for breast...
- drug
lapatinib was
approved by the U.S. FDA to
treat advanced-stage or
metastatic breast cancer in
combination with Roche's capecitabine.
Lapatinib eliminates...
- 8
months (30.9
months vs. 25.1 months)
compared to the
combination of
lapatinib and capecitabine.
Based on that trial, the U.S. Food and Drug Administration...
-
while attempting to
determine the
toxicity and
effectiveness of the drug.
Lapatinib, FDA-approved for
treatment in
conjunction with
chemotherapy or hormone...
-
Lantidra Lantrisul Lantus (Sanofi-Aventis)
lapaquistat acetate (USAN)
lapatinib ditosylate (USAN)
lapirium chloride (INN)
laprafylline (INN) la****ucel-T...
- this setting.
Sorafenib (Nexavar)
Sunitinib (Sutent)
Dasatinib (Sprycel)
Lapatinib (Tykerb)
Nilotinib (Tasigna)
Bosutinib (Bosulif)
Ponatinib (Iclusig) Asciminib...
- trastuzumab-containing
combination therapies (with chemotherapy,
hormone blockers, or
lapatinib) for the
treatment of
metastatic breast cancer.[clarification needed]...
-
antibody margetuximab can also
prolong survival, as can HER2
inhibitors lapatinib, neratinib, or tucatinib.
Certain therapies are
targeted at
those whose...
-
proliferation and
migration is diminished. Gefitinib, erlotinib,
brigatinib and
lapatinib (mixed EGFR and ERBB2 inhibitor) are
examples of
small molecule kinase...
- to
develop new
therapeutic strategies. HER2
kinase inhibitors, such as
lapatinib, have also
demonstrated clinical efficacy in HER2
overexpressing breast...
